Skip to main content
锦好医疗 logo

锦好医疗 — Investor Relations & Filings

Ticker · 920925 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 568 across all filing types
Latest filing 2023-12-06 Governance Information
Country CN China
Listing Beijing Stock Exchange 920925

About 锦好医疗

https://www.jinghao.cn/

Jinghao Medical specializes in the research, development, and manufacturing of hearing aids and home medical electronic products. The company's core portfolio includes digital and analog hearing aids, medical nebulizers, and electronic blood pressure monitors. It focuses on providing hearing health solutions by integrating advanced digital signal processing technology into its devices. Jinghao Medical operates extensively in the global market, offering original design manufacturing (ODM) and original equipment manufacturing (OEM) services to international partners. The organization emphasizes technological innovation and maintains rigorous quality management systems to comply with international medical device standards. Its primary objective is to deliver accessible, high-performance medical equipment designed to improve the quality of life for users with hearing loss and other chronic health conditions.

Recent filings

Filing Released Lang Actions
独立董事专门会议工作制度
Governance Information Classification · 95% confidence The document is titled '独立董事专门会议工作制度' which translates to 'Independent Directors Special Meeting Work System'. It details the rules and procedures for independent directors' meetings, including governance structure, meeting convening, voting, and record-keeping. It references company law, securities law, and listing rules, indicating it is a governance-related document. There is no financial data, no audit information, no earnings or capital updates, nor any shareholder voting results. The document is a formal announcement of governance procedures and internal rules related to board operations. Therefore, it fits best under Governance Information (CGR). The document length is 2159 characters, which is relatively short but contains substantive governance content, not just an announcement of a report. Hence, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2023-12-06 Chinese
关于召开2023年第四次临时股东大会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2023 fourth extraordinary general meeting of shareholders (临时股东大会) for Huizhou Jin Hao Medical Technology Co., Ltd. It details the meeting date, voting methods (including online voting), agenda items such as board elections and reappointment of the audit firm, and procedural information for shareholders. The document does not contain actual financial statements or detailed financial analysis but serves as an official announcement of the meeting and its agenda. The document length is 3550 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2023-12-06 Chinese
独立董事提名人声明与承诺（李忠轩）
Board/Management Information Classification · 95% confidence The document is a nomination statement and declaration for an independent director candidate (李忠轩) for the board of 惠州市锦好医疗科技股份有限公司. It contains detailed qualifications, compliance with laws and regulations, and declarations of independence and absence of conflicts of interest. There are no financial statements, earnings data, or report attachments. The document is an announcement related to board/management changes, specifically the nomination of a new independent director candidate. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on nomination, not a full report or regulatory filing.
2023-12-06 Chinese
独立董事提名人声明与承诺（丘小乐）
Board/Management Information Classification · 100% confidence The document is a formal announcement from the board of Huizhou Jin Hao Medical Technology Co., Ltd. nominating an independent director candidate, Qiu Xiaole. It contains detailed statements and commitments regarding the candidate's qualifications, independence, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management information, specifically the nomination of a board member. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or regulatory filing, but a substantive announcement about board nomination.
2023-12-06 Chinese
第二届董事会独立董事专门会议第一次会议的审查意见
Board/Management Information Classification · 95% confidence The document is a formal announcement from the independent directors of Huizhou Jin Hao Medical Technology Co., Ltd. regarding their review opinions on several board matters, including director nominations, expected related party transactions, and the proposal to reappoint the auditing firm. It references compliance with company law and securities regulations, and it is a statement of opinions and approvals rather than a full report or financial statements. The document length is short (1399 characters), and it serves as a board/management information announcement about board nominations and related governance matters. Therefore, it fits best under the category of Board/Management Information (MANG).
2023-12-06 Chinese
回购进展情况公告
Transaction in Own Shares Classification · 95% confidence The document is titled as a "回购进展情况公告" which translates to "Repurchase Progress Announcement." It details the company's share repurchase plan, including the purpose, method, price, quantity, funding source, implementation period, price adjustments, and progress updates on the repurchase. It includes specific numbers of shares repurchased, prices paid, and percentages of completion. The document is an announcement about the progress of the company's share buyback program rather than the buyback transaction itself or a financial report. This fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares. The document length is 1781 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is POS with high confidence.
2023-11-30 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.